Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medistim ASALTS:0OCD 100 10-Year RORE % is 33.57 as of Mar. 2026. GuruFocus rates LTS:0OCD with a GF Score™ of 100/100 and a GF Value™ of kr260.85 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 428 Medical Devices & Instruments companies, Medistim ASA ranks better than 90.42% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Medistim ASA's 10-Year RORE % for the quarter that ended in Mar. 2026 was 33.57%.
The industry rank for Medistim ASA's 10-Year RORE % or its related term are showing as below:
LTS:0OCD's 10-Year RORE % is ranked better than 90.42% of 428
companies
in the Medical Devices & Instruments industry
Industry Median: 0.955
vs LTS:0OCD: 33.57
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Medistim ASA 10-Year RORE % Related Terms
Medistim ASA 10-Year RORE % Historical Data
* Premium members only.
The historical data trend for Medistim ASA's 10-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0OCD vs ABT, SYK, MDT: 10-Year RORE % Comparison
For the Medical Devices subindustry, Medistim ASA's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medistim ASA 10-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medistim ASA's 10-Year RORE % distribution charts can be found below:
* The bar in red indicates where Medistim ASA's 10-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 10-year before.
Medistim ASA (LTS:0OCD) has a 10-Year RORE % of 33.57 as of Mar. 2026. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Medistim ASA and its competitors. According to the industry distribution chart, Medistim ASA ranks #41 out of 428 companies in the Medical Devices & Instruments industry, placing it in the top 9.6%.
Is Medistim ASA's 10-Year RORE % too high?
Medistim ASA's current 10-Year RORE % is 33.57. The Medical Devices & Instruments industry median 10-Year RORE % is 0.96. Medistim ASA's value of 33.57 is 3415.2% above this industry median. Based on the distribution chart, Medistim ASA ranks #41 out of 428 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Medistim ASA has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medistim ASA's 10-Year RORE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medistim ASA ranks #41 out of 428 companies for 10-Year RORE %. This places Medistim ASA in the top 10% of its industry — outperforming the majority of peers. The industry median 10-Year RORE % is 0.96. Medistim ASA's value of 33.57 is 3415.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Medical Devices & Instruments company?
The median 10-Year RORE % among Medical Devices & Instruments companies is 0.96, based on 428 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medistim ASA's current 10-Year RORE % of 33.57 is 3415.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Medistim ASA and its competitors. For the Medical Devices & Instruments industry, the median 10-Year RORE % is 0.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medistim ASA's current 10-Year RORE % is 33.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medistim ASA stock overvalued right now?
Based on GuruFocus' analysis, Medistim ASA (LTS:0OCD) is currently considered Modestly Undervalued. The stock's GF Value™ is kr260.85, compared to a current price of kr231.00 — trading 11.4% below its estimated fair value. The current 10-Year RORE % is 33.57 and 3415.2% above the Medical Devices & Instruments industry median of 0.96. Medistim ASA's overall GF Score™ is 100/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For Medistim ASA (LTS:0OCD), the current 10-Year RORE % is 33.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medistim ASA (LTS:0OCD) Overvalued in 2026?
Based on GuruFocus' analysis, Medistim ASA stock appears to be undervalued.
The current stock price of kr231.00 is trading 11.4% below its estimated GF Value™ of kr260.85.
GuruFocus considers Medistim ASA to be Modestly Undervalued.
Key valuation signals for LTS:0OCD:
10-Year RORE %: 33.57
GF Value™: kr260.85 vs. price of kr231.00 (11.4% below fair value)
Industry Position: 3415.2% above the Medical Devices & Instruments median (#41 of 428)
No single metric tells the full story. See the LTS:0OCD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medistim ASA is a medical device company. It is engaged in researching, developing, producing, distributing, and sales of medical equipment through its own business or participation in other companies, as well as related activities. The company's business is focused on cardiac and vascular surgery. The group operates in the USA, Europe, China, and the Rest of the World. The main divisions are sale of own products and sale of third-party products. Sale of own products has two business models, the capital model and the lease model. Third-party products segment sells medical devices from third party manufacturers in Norway, Sweden and Denmark. Key revenue is generated from Own Products segment.
100GF Score
Get the complete analysis for LTS:0OCD
10-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0OCD has been successfully added to your 
